CORDIS
EU research results

CORDIS

English EN

Highly innovative strategies for vaccination to poverty related diseases

Project information

Grant agreement ID: 36871

  • Start date

    1 January 2007

  • End date

    30 June 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 2 484 842

  • EU contribution

    € 2 000 000

Coordinated by:

ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE

United Kingdom

Objective

The Innovac project comprises seven partners of whom two are SMEs. Due to the number of SMEs the project will be coordinated by an academic partner. SMEs will have rights of first refusal to the commercial exploitation of the work they participate in.
The consortium will develop three platform technologies that will be used for novel and highly innovative methods for vaccination against two of the most important poverty related diseases, TB and Malaria. An important aspect to this proposal is inclusion of a vaccine-producing SME from a developing country.
The three platforms are
1) Bacterial spores. Robust and heat-stable bioparticles with proven efficacy as mucosal vaccines,
2) Intracellular & Invasive bacteria including E. coli strains and Mycobacterium bovis (rBCG),
3) S-layer protein conjugates and S-layer protein coated liposomes, Innovac will focus on discovery activities including proof of principle studies to show Ag expression, testing of vaccines in vitro as well as challenge experiments in vivo.
The project will test and evaluate highly novel strategies for vaccination using recombinant systems, some in their infancy while others more developed.
This project will include construction of vaccine vehicles, their evaluation in animal models, challenge experiments and finally safety tests where appropriate to take potential vaccines to the stage of clinical evaluation. Inclusion of a commercial enterprise from a developing platform will enable technology transfer to that partner as well as resources to the European partners.

Coordinator

ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE

Address

Egham Hill
Egham

United Kingdom

Participants (6)

COBRA BIOMANUFACTURING PLC

United Kingdom

NANO S BIOTECHNOLOGIE GMBH

Austria

UNIVERSITA' CATTOLICA DEL SACRO CUORE

Italy

BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE

Germany

THE COMPANY FOR VACCINE AND BIOLOGICAL PRODUCTION NO. 1

Vietnam

UNIVERSITÀ DEGLI STUDI DI PADOVA

Italy

Project information

Grant agreement ID: 36871

  • Start date

    1 January 2007

  • End date

    30 June 2010

Funded under:

FP6-LIFESCIHEALTH

  • Overall budget:

    € 2 484 842

  • EU contribution

    € 2 000 000

Coordinated by:

ROYAL HOLLOWAY AND BEDFORD NEW COLLEGE

United Kingdom